Maintenance Proton Pump Inhibitor Use Associated with Increased All-Cause and Cause-Specific Mortality in Sweden
Open Access
- 11 January 2023
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 68 (6) , 2252-2263
Abstract
Background Proton pump inhibitor (PPI) use has increased over the last decades and has been associated with multiple adverse events and potentially even overall survival. Aims We aimed to investigate the association between proton pump inhibitor maintenance use and all-cause and cause-specific mortality, addressing confounding by indication and duration of use. Methods This Swedish population-based cohort study included all adult (N = 935,236) PPI and histamine-2 receptor antagonist maintenance users (≥ 180 days use) during 2005–2014. Standardised mortality ratios (SMRs) and 95% confidence intervals were calculated for all-cause and cause-specific mortality comparing the risk among PPI/H2RA users to that of the Swedish background population, stratified by age, sex, calendar period, indication and duration of use. Multivariable Poisson regression models were used to compare PPI use to H2RA use, expressed as incidence rate ratios and 95% confidence intervals. Results PPI and histamine-2 receptor antagonist use were associated with an increased risk of all-cause mortality (SMR = 1.35; 1.34–1.36; SMR = 1.31; 1.27–1.36, respectively). The highest SMRs were found in the youngest age groups. In direct comparison, PPI use showed a higher mortality risk than histamine-2 receptor antagonist use (incidence rate ratios = 1.42; 1.38–1.46). PPIs were related to increased cancer (SMR = 1.21; 1.20–1.22), and cardiovascular mortality (SMR = 1.36; 1.35–1.37). Increased SMRs were observed for most indications. Longer duration of use was associated with a higher mortality among PPI users but not among histamine-2 receptor antagonist users. Conclusion Maintenance PPI use was associated with an increased risk of all-cause and cause-specific mortality, and the risk increased with prolonged duration.Keywords
Funding Information
- Vetenskapsrådet
- Karolinska Institute
This publication has 52 references indexed in Scilit:
- Proton pump inhibitors affect the gut microbiomeGut, 2015
- Gastric Cancer in the Young: Is It a Different Clinical Entity? A Retrospective Cohort StudyGastroenterology Research and Practice, 2014
- Proton Pump Inhibitors and Risk of 1-Year Mortality and Rehospitalization in Older Patients Discharged From Acute Care HospitalsJAMA Internal Medicine, 2013
- Association between Helicobacter pylori and mortality in the NHANES III studyGut, 2013
- Risk of Death Associated With Use of PPIs in Three Cohorts of Institutionalized Older People in FinlandJournal of the American Medical Directors Association, 2012
- External review and validation of the Swedish national inpatient registerBMC Public Health, 2011
- Overprescribing proton pump inhibitorsBMJ, 2008
- Discontinuation of proton pump inhibitors in patients on long‐term therapy: a double‐blind, placebo‐controlled trialAlimentary Pharmacology & Therapeutics, 2006
- Review article: the long‐term use of proton‐pump inhibitorsAlimentary Pharmacology & Therapeutics, 2005
- Comparing Swedish hospital discharge records with death certificates: implications for mortality statisticsInternational Journal of Epidemiology, 2000